It's a good point about having surplus funds available when negotiating a deal. I made the point last July that it's a terrible starting point for negotiations when your cash is running low. Having our head over a barrel won't lead to value being released for shareholders.
So whilst there is dilution, it should be outweighed by the strengthening bargaining position.
Everything else sounds as expected. We really do wait until the end of this calendar year for the sale/auction and hope in the interim we can produce a great V3.0 product with plenty of analytics and positive clinical trial results.
ALT Price at posting:
0.6¢ Sentiment: Hold Disclosure: Held
